In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Compugen (CGEN – Research Report), with a price target of $4.00. The company’s shares closed last Friday at $1.46.
According to TipRanks, Benjamin is an analyst with an average return of -5.2% and a 36.95% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Incyte, and Seagen.
Currently, the analyst consensus on Compugen is a Moderate Buy with an average price target of $5.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $7.48 and a one-year low of $1.39. Currently, Compugen has an average volume of 884.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.
Read More on CGEN:
- Analysts Have Conflicting Sentiments on These Healthcare Companies: Iovance Biotherapeutics (IOVA), Cellectis SA (CLLS) and Orthofix (OFIX)
- JMP Securities Sticks to Its Hold Rating for NextCure (NXTC)
- JMP Securities Sticks to Their Buy Rating for Generation Bio (GBIO)
- Positive Report for OZ Minerals Limited (OZMLF) from Ord Minnett
- Rosenblatt Securities Sticks to Its Buy Rating for IMAX (IMAX)
